VINCERX PHARMA INC. -

Vincerx Pharma Reports Third Quarter 2024 Financial Results

12 11 2024 08:00:01 提供 Nasdaq GlobeNewswire

Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates

07 10 2024 15:05:00 提供 Nasdaq GlobeNewswire

Vincerx Pharma Reports Second Quarter 2024 Financial Results

08 8 2024 15:30:00 提供 Nasdaq GlobeNewswire

Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

14 5 2024 15:15:00 提供 Nasdaq GlobeNewswire

Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants

25 4 2024 23:27:06 提供 Nasdaq GlobeNewswire

Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants

25 4 2024 15:01:00 提供 Nasdaq GlobeNewswire

Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024 

08 4 2024 15:30:00 提供 Nasdaq GlobeNewswire

Vincerx to Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

01 4 2024 07:00:01 提供 Nasdaq GlobeNewswire

Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

29 3 2024 14:20:52 提供 Nasdaq GlobeNewswire

Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024

05 3 2024 15:31:00 提供 Nasdaq GlobeNewswire

Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma

07 1 2024 14:00:00 提供 Nasdaq GlobeNewswire

Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023

10 12 2023 11:00:00 提供 Nasdaq GlobeNewswire

Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update

14 11 2023 06:00:00 提供 Nasdaq GlobeNewswire

Vincerx Pharma To Present Three Posters at ASH 2023 in December

02 11 2023 08:10:00 提供 Nasdaq GlobeNewswire

Vincerx Pharma to Participate at the Cantor Fitzgerald Global Healthcare Conference 2023

19 9 2023 06:00:00 提供 Nasdaq GlobeNewswire

Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943

14 9 2023 06:00:00 提供 Nasdaq GlobeNewswire

Vincerx Pharma Announces FDA Clearance of IND for VIP943

22 8 2023 06:30:09 提供 Nasdaq GlobeNewswire

Vincerx Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update

07 8 2023 08:25:00 提供 Nasdaq GlobeNewswire

Vincerx Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

11 5 2023 15:05:01 提供 Nasdaq GlobeNewswire

Vincerx Pharma Presents Preclinical Data on VIP924, a First-in-Class Antibody-Drug Conjugate (ADC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting

19 4 2023 08:05:00 提供 Nasdaq GlobeNewswire